Abbott Laboratories (ABT) Stock Forecast & Price Target

Compare

8,772 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

ABT Analyst Ratings

Strong Buy

18 Buy

2 Hold

0 Sell

Based on 20 analysts giving stock ratings to

Abbott

Laboratories

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

ABT Stock 12 Month Forecast

Average Price Target

$146.63

▲(14.07% Upside)

Based on 20 Wall Street analysts offering 12 month price targets for Abbott Laboratories in the last 3 months. The average price target is $146.63 with a high forecast of $162.00 and a low forecast of $136.00. The average price target represents a 14.07% change from the last price of $128.54.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"109":"$109","136":"$136","163":"$163","122.5":"$122.5","149.5":"$149.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":162,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$162.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":146.63,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$146.63</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":136,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$136.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[109,122.5,136,149.5,163],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"Apr<br/>2025","9":"Jul<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,132.88,135.12,137.35999999999999,139.6,141.84,144.07999999999998,146.32,148.56,150.8,153.04,155.28,157.51999999999998,159.76,{"y":162,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,132.88,133.93769230769232,134.9953846153846,136.05307692307693,137.11076923076922,138.16846153846154,139.22615384615384,140.28384615384616,141.34153846153845,142.39923076923077,143.45692307692306,144.51461538461538,145.57230769230767,{"y":146.63,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,132.88,133.12,133.35999999999999,133.6,133.84,134.07999999999998,134.32,134.56,134.8,135.04,135.28,135.52,135.76,{"y":136,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":110.92,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":116.39,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 45,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":114.64,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 53,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":111.01,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 50,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":126.21,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":136.15,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":129.92,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":129.72,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 49,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":132.38,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 42,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":135.05,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 45,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":126.73,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":130.88,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":132.88,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$162.00

Average Price Target$146.63

Lowest Price Target$136.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Matt Miksic

Barclays

$159→$162

Buy

26.03%

Upside

Reiterated

10/17/25

Abbott Laboratories (ABT) Gets a Buy from Barclays

Danielle Antalffy

UBS

$154→$158

Buy

22.92%

Upside

Reiterated

10/17/25

Analysts Are Bullish on Top Healthcare Stocks: Abbott Laboratories (ABT), Achieve Life Sciences (ACHV)

Patrick Wood

Morgan Stanley

$137

Hold

6.58%

Upside

Reiterated

10/17/25

Morgan Stanley Remains a Hold on Abbott Laboratories (ABT)Abbott Laboratories: Equal-Weight; Price Target current 137.00 and previous 137.00; EPS estimates revised from 5.13 to 5.14 and 5.58 to 5.68

Jayson Bedford

Raymond James

$141→$146

Buy

13.58%

Upside

Reiterated

10/16/25

Abbott price target raised to $146 from $141 at Raymond JamesAbbott price target raised to $146 from $141 at Raymond James

Joanne Wuensch

Citi

―

Buy

―

Reiterated

10/16/25

Citi Sticks to Its Buy Rating for Abbott Laboratories (ABT)

Larry Biegelsen

Wells Fargo

$142→$146

Buy

13.58%

Upside

Reiterated

10/16/25

Abbott price target raised to $146 from $142 at Wells FargoAbbott price target raised to $146 from $142 at Wells Fargo

Mike Kratky

Leerink Partners

$136

Hold

5.80%

Upside

Reiterated

10/16/25

Analysts Conflicted on These Healthcare Names: Abbott Laboratories (NYSE: ABT), Amgen (NASDAQ: AMGN) and Pharvaris (NASDAQ: PHVS)

Vijay Kumar

Evercore ISI

$144→$142

Buy

10.47%

Upside

Reiterated

10/16/25

Abbott price target lowered to $142 from $144 at Evercore ISIAbbott price target lowered to $142 from $144 at Evercore ISI

Lila Implantra

TR | OpenAI - 4o

$153→$147

Buy

14.36%

Upside

Reiterated

10/16/25

AI Generated ArticleAI Generated Article

Bruce Jackson

Benchmark Co.

$145

Buy

12.81%

Upside

Reiterated

10/16/25

Abbott Laboratories (ABT) Gets a Buy from Benchmark Co.

Robbie Marcus

J.P. Morgan

$145

Buy

12.81%

Upside

Reiterated

10/15/25

Analysts Offer Insights on Healthcare Companies: Align Tech (NASDAQ: ALGN), Perrigo Company (NYSE: PRGO) and Abbott Laboratories (NYSE: ABT)

Travis Steed

Bank of America Securities

$150

Buy

16.70%

Upside

Reiterated

10/15/25

Abbott Laboratories: Strong Growth Prospects and Stable Financial Health Drive Buy RatingWe expect 2025 op margin will stay around 23.5%. We also think ABT will be comfortable with the Street’s 2026 estimate of 7.5% growth and 10% EPS growth. Dx likely returns to growth next year in the mid-single digit range. A few dynamics in the quarter that stood out Nutrition grew 4% vs our 5% expectation. Nutrition was a little lighter than expected in Q3 given some competitive impact in US peds (ABT captured share last year from a competitor during a supply disruption and some of that share moved back to the competitor). A loss of a WIC contract also impacted growth. There was also a tough comp in the adult nutrition business. US diabetes was flat q/q but the usual seasonal dynamics is harder to see in 2025 given the supply dynamics.

Josh Jennings

TD Cowen

$145

Buy

12.81%

Upside

Reiterated

10/15/25

Strong Performance and Future Potential: Buy Rating for Abbott Laboratories9:16 PM Abbott Laboratories (NYSE: ABT) Buy (1) ESG $145.00 High Expectations Fuel Post-Print Pullback, But 2026 Outlook Remains Attractive View Full Report THE TD COWEN INSIGHT We view the Q3 report as solid. Revenue and EPS essentially matched Street expectations. Ex-COVID organic growth was 7.5%, and Med Devices had another standout performance, with 12.5% growth. ABT maintained its full-year ex-COVID organic sales growth guidance of 7.5-8% and the $5.15 midpoint of its full-year EPS guidance. For 2026, ABT said it is "very comfortable" with Street's current estimates. Revenue was $11.37B compared to the Street estimate of $11.39B.

Shagun Singh Chadha

RBC Capital

$147

Buy

14.36%

Upside

Reiterated

10/15/25

RBC Capital Keeps Their Buy Rating on Abbott Laboratories (ABT)

Brandon Vazquez

William Blair

―

Buy

―

Reiterated

10/15/25

Promising Growth Prospects for Abbott Laboratories Amid Short-term Challenges: A Buy Rating by Brandon Vazquez

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Matt Miksic

Barclays

$159→$162

Buy

26.03%

Upside

Reiterated

10/17/25

Abbott Laboratories (ABT) Gets a Buy from Barclays

Danielle Antalffy

UBS

$154→$158

Buy

22.92%

Upside

Reiterated

10/17/25

Analysts Are Bullish on Top Healthcare Stocks: Abbott Laboratories (ABT), Achieve Life Sciences (ACHV)

Patrick Wood

Morgan Stanley

$137

Hold

6.58%

Upside

Reiterated

10/17/25

Morgan Stanley Remains a Hold on Abbott Laboratories (ABT)Abbott Laboratories: Equal-Weight; Price Target current 137.00 and previous 137.00; EPS estimates revised from 5.13 to 5.14 and 5.58 to 5.68

Jayson Bedford

Raymond James

$141→$146

Buy

13.58%

Upside

Reiterated

10/16/25

Abbott price target raised to $146 from $141 at Raymond JamesAbbott price target raised to $146 from $141 at Raymond James

Joanne Wuensch

Citi

―

Buy

―

Reiterated

10/16/25

Citi Sticks to Its Buy Rating for Abbott Laboratories (ABT)

Larry Biegelsen

Wells Fargo

$142→$146

Buy

13.58%

Upside

Reiterated

10/16/25

Abbott price target raised to $146 from $142 at Wells FargoAbbott price target raised to $146 from $142 at Wells Fargo

Mike Kratky

Leerink Partners

$136

Hold

5.80%

Upside

Reiterated

10/16/25

Analysts Conflicted on These Healthcare Names: Abbott Laboratories (NYSE: ABT), Amgen (NASDAQ: AMGN) and Pharvaris (NASDAQ: PHVS)

Vijay Kumar

Evercore ISI

$144→$142

Buy

10.47%

Upside

Reiterated

10/16/25

Abbott price target lowered to $142 from $144 at Evercore ISIAbbott price target lowered to $142 from $144 at Evercore ISI

Lila Implantra

TR | OpenAI - 4o

$153→$147

Buy

14.36%

Upside

Reiterated

10/16/25

AI Generated ArticleAI Generated Article

Bruce Jackson

Benchmark Co.

$145

Buy

12.81%

Upside

Reiterated

10/16/25

Abbott Laboratories (ABT) Gets a Buy from Benchmark Co.

Robbie Marcus

J.P. Morgan

$145

Buy

12.81%

Upside

Reiterated

10/15/25

Analysts Offer Insights on Healthcare Companies: Align Tech (NASDAQ: ALGN), Perrigo Company (NYSE: PRGO) and Abbott Laboratories (NYSE: ABT)

Travis Steed

Bank of America Securities

$150

Buy

16.70%

Upside

Reiterated

10/15/25

Josh Jennings

TD Cowen

$145

Buy

12.81%

Upside

Reiterated

10/15/25

Shagun Singh Chadha

RBC Capital

$147

Buy

14.36%

Upside

Reiterated

10/15/25

RBC Capital Keeps Their Buy Rating on Abbott Laboratories (ABT)

Brandon Vazquez

William Blair

―

Buy

―

Reiterated

10/15/25

Promising Growth Prospects for Abbott Laboratories Amid Short-term Challenges: A Buy Rating by Brandon Vazquez

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Abbott Laboratories

1 Month

xxx

Success Rate

32/45 ratings generated profit

Average Return

+2.41%

reiterated a xxx

rating 5 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 71.11% of your transactions generating a profit, with an average return of +2.41% per trade.

3 Months

xxx

Success Rate

22/29 ratings generated profit

Average Return

+5.00%

reiterated a xxx

rating 4 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 75.86% of your transactions generating a profit, with an average return of +5.00% per trade.

1 Year

Rick WiseStifel Nicolaus

Success Rate

21/23 ratings generated profit

Average Return

+14.16%

reiterated a buy rating 3 months ago

Copying Rick Wise's trades and holding each position for 1 Year would result in 91.30% of your transactions generating a profit, with an average return of +14.16% per trade.

2 Years

xxx

Success Rate

19/25 ratings generated profit

Average Return

+14.11%

reiterated a xxx

rating 6 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 76.00% of your transactions generating a profit, with an average return of +14.11% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ABT Analyst Recommendation Trends

Rating

Jun 25

Jul 25

Aug 25

Sep 25

Oct 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, ABT has received 32 Buy Ratings, 3 Hold Ratings, and 0 Sell Ratings. ABT average Analyst price target in the past 3 months is 146.63.

Each month's total comprises the sum of three months' worth of ratings.

ABT Financial Forecast

ABT Earnings Forecast

Next quarter’s earnings estimate for ABT is $1.50 with a range of $1.44 to $1.51. The previous quarter’s EPS was $1.30. ABT beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.09% of the time in the same period. In the last calendar year ABT has Preformed in-line its overall industry.

ABT Sales Forecast

Next quarter’s sales forecast for ABT is $11.80B with a range of $11.62B to $11.89B. The previous quarter’s sales results were $11.37B. ABT beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.55% of the time in the same period. In the last calendar year ABT has Preformed in-line its overall industry.

ABT Stock Forecast FAQ

What is ABT’s average 12-month price target, according to analysts?

Based on analyst ratings, Abbott Laboratories’s 12-month average price target is 146.63.

What is ABT’s upside potential, based on the analysts’ average price target?

Abbott Laboratories has 14.07% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is ABT a Buy, Sell or Hold?

Abbott Laboratories has a consensus rating of Strong Buy which is based on 18 buy ratings, 2 hold ratings and 0 sell ratings.

What is Abbott Laboratories’s price target?

The average price target for Abbott Laboratories is 146.63. This is based on 20 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $162.00 ,the lowest forecast is $136.00. The average price target represents 14.07% Increase from the current price of $128.54.

What do analysts say about Abbott Laboratories?

Abbott Laboratories’s analyst rating consensus is a Strong Buy. This is based on the ratings of 20 Wall Streets Analysts.

How can I buy shares of ABT?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Abbott Laboratories (ABT) Stock Forecast & Price Target

ABT Analyst Ratings

ABT Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Abbott Laboratories

ABT Analyst Recommendation Trends

ABT Financial Forecast

ABT Earnings Forecast

ABT Sales Forecast

ABT Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts